Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31023317)

  • 1. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
    J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.
    Lai ZY; Tsai KY; Chang SJ; Chuang YJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
    Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
    Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of CCDC69 activates p14
    Cui L; Zhou F; Chen C; Wang CC
    J Ovarian Res; 2019 Jan; 12(1):4. PubMed ID: 30651135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
    Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
    J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.
    Xie X; Lozano G; Siddik ZH
    Oncogene; 2016 Sep; 35(36):4798-806. PubMed ID: 26876197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
    Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
    Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
    Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
    Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
    Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
    Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
    Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 protein aggregation promotes platinum resistance in ovarian cancer.
    Yang-Hartwich Y; Soteras MG; Lin ZP; Holmberg J; Sumi N; Craveiro V; Liang M; Romanoff E; Bingham J; Garofalo F; Alvero A; Mor G
    Oncogene; 2015 Jul; 34(27):3605-16. PubMed ID: 25263447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
    Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
    Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
    Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB.
    Son DS; Kabir SM; Dong YL; Lee E; Adunyah SE
    PLoS One; 2012; 7(12):e51116. PubMed ID: 23300534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
    Makii C; Oda K; Ikeda Y; Sone K; Hasegawa K; Uehara Y; Nishijima A; Asada K; Koso T; Fukuda T; Inaba K; Oki S; Machino H; Kojima M; Kashiyama T; Mori-Uchino M; Arimoto T; Wada-Hiraike O; Kawana K; Yano T; Fujiwara K; Aburatani H; Osuga Y; Fujii T
    Oncotarget; 2016 Nov; 7(46):75328-75338. PubMed ID: 27659536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.
    Farrand L; Byun S; Kim JY; Im-Aram A; Lee J; Lim S; Lee KW; Suh JY; Lee HJ; Tsang BK
    J Biol Chem; 2013 Aug; 288(33):23740-50. PubMed ID: 23833193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.